Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Cell ; 2024 Jun 28.
Article in English | MEDLINE | ID: mdl-38968937

ABSTRACT

Immune tolerance mechanisms are shared in cancer and pregnancy. Through cross-analyzing single-cell RNA-sequencing data from multiple human cancer types and the maternal-fetal interface, we found B7-H4 (VTCN1) is an onco-fetal immune tolerance checkpoint. We showed that genetic deficiency of B7-H4 resulted in immune activation and fetal resorption in allogeneic pregnancy models. Analogously, B7-H4 contributed to MPA/DMBA-induced breast cancer progression, accompanied by CD8+ T cell exhaustion. Female hormone screening revealed that progesterone stimulated B7-H4 expression in placental and breast cancer cells. Mechanistically, progesterone receptor (PR) bound to a newly identified -58 kb enhancer, thereby mediating B7-H4 transcription via the PR-P300-BRD4 axis. PR antagonist or BRD4 degrader potentiated immunotherapy in a murine B7-H4+ breast cancer model. Thus, our work unravels a mechanistic and biological connection of a female sex hormone (progesterone) to onco-fetal immune tolerance via B7-H4 and suggests that the PR-P300-BRD4 axis is targetable for treating B7-H4+ cancer.

2.
Breast Cancer Res Treat ; 203(2): 383-396, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37847455

ABSTRACT

PURPOSE: Estrogen Receptor α (ERα) is a well-established therapeutic target for Estrogen Receptor (ER)-positive breast cancers. Both Selective Estrogen Receptor Degraders (SERD) and PROTAC ER degraders are synthetic compounds suppressing the ER activity through the degradation of ER. However, the differences between SERD and PROTAC ER degraders are far from clear. METHODS: The effect of PROTAC ER degrader ERD-148 and SERD fulvestrant on protein degradation was evaluated by western blot analysis. The cell proliferation was tested by WST-8 assays and the gene expressions were assessed by gene microarray and real-time RT-PCR analysis after the compound treatment. RESULTS: ERD-148 is a potent and selective PROTAC ERα degrader. It degrades not only unphosphorylated ERα but also the phosphorylated ERα in the cells. In contrast, the SERD fulvestrant showed much-reduced degradation potency on the phosphorylated ERα. The more complete degradation of ERα by ERD-148 translates into a greater maximum cell growth inhibition. However, ERD-148 and fulvestrant share a similar gene regulation profile except for the variation of regulation potency. Further studies indicate that ERD-148 degrades the ERα in fulvestrant-resistant cells. CONCLUSION: PROTAC ER degrader has a different mechanism of action compared to SERD which may be used in treating fulvestrant-resistant cancers.


Subject(s)
Breast Neoplasms , Estrogen Receptor alpha , Female , Humans , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Estrogen Antagonists/pharmacology , Estrogen Receptor alpha/metabolism , Fulvestrant/pharmacology , Selective Estrogen Receptor Modulators/pharmacology
3.
Mol Phylogenet Evol ; 186: 107871, 2023 09.
Article in English | MEDLINE | ID: mdl-37422179

ABSTRACT

The genus Odontobutis is a group of freshwater fishes endemic to East Asia. Phylogenetic relationships among the Odontobutis species have never been fully tested due to incomplete taxon sampling and that molecular data have not been collected in many Odontobutis species. In the present study, we sampled 51 specimens from all known eight Odontobutis species with two outgroups (Perccottus glenii and Neodontobutis hainanensis). We collected sequence data of 4434 single-copy nuclear coding loci using gene capture and Illumina sequencing. A robust phylogeny of the Odontobutis with many individuals for each species was built, supporting the current taxonomy that all extant Odontobutis species are valid. The two species from Japan (O. hikimius + O. obscurus) formed an independent clade sister to the "continental odontobutids", whereas the species from southern China (O. sinensis + O. haifengensis) separated from the rest species of the genus. Surprisingly species from the lower reaches of the Yangtze River (O. potamophilus) was more closely related to species from the Korean Peninsula and northeastern China than to the middle reaches of the Yangtze River, such that their relationship was ((O. sinensis + O. haifengensis)(O. platycephala + (O. yaluensis + (O. potamophilus + O. interruptus)))). Divergence time among the Odontobutis was estimated using 100 most clock-like loci and three fossil calibration points. The crown group of the Odontobutis was estimated at 9.0 Ma during the late Miocene (5.6-12.7 Ma, 95% HPDs). Ancestral range of the genus was reconstructed using Reconstruct Ancestral States in Phylogenies (RASP) and BioGeoBEARS. The result suggested that the common ancestor of modern Odontobutis probably was distributed in Japan, southern China or the Korean Peninsula. A series of geographical events in East Asia since the late Miocene, such as the opening of the Japan/East Sea, rapid uplift of the Tibetan Plateau and climate change in the northern region of the Yellow River might account for diversification and current distribution pattern of the Odontobutis.


Subject(s)
Perciformes , Animals , Phylogeny , Sequence Analysis, DNA , Asia, Eastern , Fresh Water , Phylogeography
4.
J Med Chem ; 66(12): 8222-8237, 2023 06 22.
Article in English | MEDLINE | ID: mdl-37289649

ABSTRACT

Starting from a nonselective bromodomain and extraterminal (BET) inhibitor and a cereblon ligand, we have used precise conformational control for the development of two potent and highly selective BRD4 degraders, BD-7148 and BD-9136. These compounds induce rapid degradation of BRD4 protein in cells at concentrations as low as 1 nM and demonstrate ≥1000-fold degradation selectivity over BRD2 or BRD3 protein. Proteomic analysis of >5700 proteins confirmed their highly selective BRD4 degradation. A single dose of BD-9136 selectively and effectively depletes BRD4 protein in tumor tissues for >48 h. BD-9136 effectively inhibits tumor growth without adverse effects on mice and is more efficacious than the corresponding pan BET inhibitor. This study suggests selective degradation of BRD4 as a strategy for the treatment of human cancers and demonstrates a strategy for the design of highly selective PROTAC degraders.


Subject(s)
Neoplasms , Nuclear Proteins , Humans , Mice , Animals , Cell Cycle Proteins , Transcription Factors , Proteomics
5.
Zookeys ; 1153: 1-13, 2023.
Article in English | MEDLINE | ID: mdl-37234483

ABSTRACT

Microdousamblyrhynchos, a new species, the second one in the genus, from the family Odontobutidae, is described from the Hongshui River, in the upper reaches of the Xijiang River of the Pearl River drainage, Baise City, Guangxi Zhuang Autonomous Region, southern China. This species is distinguished from its only congener, M.chalmersi, by the blunt snout (vs. pointed); mean snout length/head length ratio 0.27 (vs. 0.3); eye not extending outward (vs. protruding); mean interorbital width/head length ratio 0.25 (vs. 0.11). Additionally, the results of molecular phylogenetic analysis confirmed that M.amblyrhynchossp. nov. is distinct from its sister species, M.chalmersi.

6.
Breast Cancer Res Treat ; 180(3): 623, 2020 04.
Article in English | MEDLINE | ID: mdl-32180072

ABSTRACT

In the original publication of the article, the spelling of the sixth author's given name was incorrect. The corrected author name should read as "Wadie David". The original article has been corrected.

7.
Breast Cancer Res Treat ; 180(3): 611-622, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32067153

ABSTRACT

PURPOSE: Studies have identified several estrogen receptor α (ERα) ligand-binding domain (LBD) somatic mutations in endocrine therapy resistant, metastatic ER-positive breast cancers. The most common mutations, Tyr537Ser (Y537S) and Asp538Gly (D538G), are detected in ~ 30% of endocrine resistant metastatic breast cancer patients. These ESR1 mutations induce the agonist conformation of ERα, confer an estrogen-independent phenotype, and promote drug resistance to antiestrogens. METHODS: ER-positive, estrogen-dependent MCF-7 cells were engineered to express either the Y537S or D538G mutants using CRISPR knock-in (cY537S and cD538G). These cells were used to screen several estrogen receptor degrader (ERD) compounds synthesized using the Proteolysis Targeting Chimeras (PROTAC) method to induce degradation of ERα via the ubiquitin-proteasome pathway. RESULTS: Wild-type MCF-7 and ERα LBD mutant cells were treated with ERD-148 (10 pM-1 µM) and assayed for cellular proliferation using the PrestoBlue cell viability assay. ERD-148 attenuated ER-dependent growth with IC50 values of 0.8, 10.5, and 6.1 nM in MCF-7, cY537S, and cD538G cells, respectively. Western blot analysis showed that MCF-7 cells treated with 1 nM ERD-148 for 24 h exhibited reduced ERα protein expression as compared to the mutants. The ER-regulated gene, GREB1, demonstrated significant downregulation in parental and mutant cells after 24 h of ERD-148 treatment at 10 nM. Growth of the ER-negative, estrogen-independent MDA-MB-231 breast cancer cells was not inhibited by ERD-148 at the ~ IC90 observed in the ER-positive cells. CONCLUSION: ERD-148 inhibits the growth of ER-positive breast cancer cells via downregulating ERα with comparable potency to Fulvestrant with marginal non-specific toxicity.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Estrogen Antagonists/pharmacology , Estrogen Receptor alpha/genetics , Estrogens/pharmacology , Mutation , Breast Neoplasms/genetics , Breast Neoplasms/pathology , CRISPR-Cas Systems , Cell Proliferation/drug effects , Estrogen Receptor alpha/antagonists & inhibitors , Estrogen Receptor alpha/metabolism , Female , Humans , Proteolysis , Tumor Cells, Cultured
8.
J Med Chem ; 62(3): 1420-1442, 2019 02 14.
Article in English | MEDLINE | ID: mdl-30990042

ABSTRACT

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-molecule ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept. Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 (32). ERD-308 achieves DC50 (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells. Further optimization of ERD-308 may lead to a new therapy for advanced ER+ breast cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Dipeptides/pharmacology , Pyrrolidines/pharmacology , Receptors, Estrogen/metabolism , Thiophenes/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Dipeptides/chemical synthesis , Dipeptides/chemistry , Drug Design , Drug Screening Assays, Antitumor , Humans , Ligands , Molecular Structure , Proteolysis , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Receptors, Estrogen/chemistry , Structure-Activity Relationship , Thiophenes/chemical synthesis , Thiophenes/chemistry , Ubiquitin-Protein Ligases/metabolism
9.
J Med Chem ; 61(15): 6685-6704, 2018 Aug 09.
Article in English | MEDLINE | ID: mdl-30019901

ABSTRACT

Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases. We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-molecule BET degraders. Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degradation of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concentrations. QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules. QCA570 is the most potent and efficacious BET degrader reported to date.


Subject(s)
Drug Design , Proteins/metabolism , Proteolysis/drug effects , Small Molecule Libraries/pharmacology , Animals , Cell Line, Tumor , Dose-Response Relationship, Drug , Female , Humans , Mice , Models, Molecular , Protein Conformation , Proteins/chemistry , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacokinetics
10.
J Med Chem ; 61(2): 462-481, 2018 01 25.
Article in English | MEDLINE | ID: mdl-28339196

ABSTRACT

The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic "readers" and play a key role in the regulation of gene transcription. BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders. One of the most promising compounds, 23, effectively degrades BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Indoles/chemistry , Indoles/pharmacology , Nuclear Proteins/metabolism , Pyrimidines/chemistry , Pyrimidines/pharmacology , Transcription Factors/metabolism , Animals , Antineoplastic Agents/chemical synthesis , Cell Cycle Proteins , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Design , Drug Screening Assays, Antitumor/methods , Female , Humans , Indoles/chemical synthesis , Leukemia/drug therapy , Mice, SCID , Nuclear Proteins/chemistry , Protein Serine-Threonine Kinases/metabolism , Proteolysis , Pyrimidines/chemical synthesis , RNA-Binding Proteins/metabolism , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Structure-Activity Relationship , Transcription Factors/chemistry , Xenograft Model Antitumor Assays
11.
ACS Appl Mater Interfaces ; 9(38): 33001-33010, 2017 Sep 27.
Article in English | MEDLINE | ID: mdl-28871780

ABSTRACT

Inspired by the microstructures of naturally layered and highly oriented materials, such as natural nacre, we report a thermally conductive polymer composite that consists of epoxy resin and Al2O3 platelets deposited with silver nanoparticles (AgNPs). Owing to their unique two-dimensional structure, Al2O3 platelets are stacked together via a hot-pressing technique, resulting in a brick-and-mortar structure, which is similar to the one of natural nacre. Moreover, the AgNPs deposited on the surfaces of the Al2O3 platelets act as bridges that link the adjacent Al2O3 platelets due to the reduced melting point of the AgNPs. As a result, the polymer composite with 50 wt % filler achieves a maximum thermal conductivity of 6.71 W m-1 K-1. In addition, the small addition of AgNPs (0.6 wt %) minimally affects the electrical insulation of the composites. Our bioinspired approach will find uses in the design and fabrication of thermally conductive materials for thermal management in modern electronics.

12.
ACS Appl Mater Interfaces ; 9(15): 13544-13553, 2017 Apr 19.
Article in English | MEDLINE | ID: mdl-28362080

ABSTRACT

In this work, we report a fabrication of epoxy resin/ordered three-dimensional boron nitride (3D-BN) network composites through combination of ice-templating self-assembly and infiltration methods. The polymer composites possess much higher thermal conductivity up to 4.42 W m-1 K-1 at relatively low loading 34 vol % than that of random distribution composites (1.81 W m-1 K-1 for epoxy/random 3D-BN composites, 1.16 W m-1 K-1 for epoxy/random BN composites) and exhibit a high glass transition temperature (178.9-229.2 °C) and dimensional stability (22.7 ppm/K). We attribute the increased thermal conductivity to the unique oriented 3D-BN thermally conducive network, in which the much higher thermal conductivity along the in-plane direction of BN microplatelets is most useful. This study paves the way for thermally conductive polymer composites used as thermal interface materials for next-generation electronic packaging and 3D integration circuits.

13.
Cancer Res ; 77(9): 2476-2487, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28209615

ABSTRACT

Triple-negative breast cancers (TNBC) remain clinically challenging with a lack of options for targeted therapy. In this study, we report the development of a second-generation BET protein degrader, BETd-246, which exhibits superior selectivity, potency, and antitumor activity. In human TNBC cells, BETd-246 induced degradation of BET proteins at low nanomolar concentrations within 1 hour of exposure, resulting in robust growth inhibition and apoptosis. BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compound BETi-211. RNA-seq analysis revealed predominant downregulation of a large number of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared with BETi-211 treatment that upregulated and downregulated a similar number of genes. Functional investigations identified the MCL1 gene as a critical downstream effector for BET degraders, which synergized with small-molecule inhibitors of BCL-xL in triggering apoptosis. In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analogue BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules. Overall, our findings show that targeting BET proteins for degradation represents an effective therapeutic strategy for TNBC treatment. Cancer Res; 77(9); 2476-87. ©2017 AACR.


Subject(s)
Antineoplastic Agents/administration & dosage , Nerve Tissue Proteins/antagonists & inhibitors , Proteolysis/drug effects , Receptors, Cell Surface/antagonists & inhibitors , Triple Negative Breast Neoplasms/drug therapy , Animals , Cell Line, Tumor , High-Throughput Nucleotide Sequencing , Humans , Mice , Myeloid Cell Leukemia Sequence 1 Protein/genetics , Nerve Tissue Proteins/genetics , Receptors, Cell Surface/genetics , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology , Xenograft Model Antitumor Assays
14.
ACS Appl Mater Interfaces ; 8(45): 31248-31255, 2016 Nov 16.
Article in English | MEDLINE | ID: mdl-27788322

ABSTRACT

Polymer composites with high thermal conductivity have attracted much attention, along with the rapid development of electronic devices toward higher speed and better performance. However, high interfacial thermal resistance between fillers and matrix or between fillers and fillers has been one of the primary bottlenecks for the effective thermal conduction in polymer composites. Herein, we report on engineering interfacial structure of silicon carbide nanowire/cellulose microcrystal paper by generating silver nanostructures. We show that silver nanoparticle-deposited silicon carbide nanowires as fillers can effectively enhance the thermal conductivity of the matrix. The in-plane thermal conductivity of the resultant composite paper reaches as high as 34.0 W/m K, which is one order magnitude higher than that of conventional polymer composites. Fitting the measured thermal conductivity with theoretical models qualitatively demonstrates that silver nanoparticles bring the lower interfacial thermal resistances both at silicon carbide nanowire/cellulose microcrystal and silicon carbide nanowire/silicon carbide nanowire interfaces. This interfacial engineering approach provides a powerful tool for sophisticated fabrication of high-performance thermal-management materials.

15.
Chem Commun (Camb) ; 51(80): 14929-32, 2015 Oct 14.
Article in English | MEDLINE | ID: mdl-26307027

ABSTRACT

A novel palladium catalyzed hydroxylation of unactivated aliphatic C(sp(3))-H bonds was successfully developed. Different from conventional methods, water serves as the hydroxyl group source in the reaction. This new reaction demonstrates good reactivity and broad functional group tolerance. The C-H hydroxylated products can be readily transformed into various highly valuable chemicals via known transformations. Based on experimental and theoretical studies, a mechanism involving the Pd(II)/(IV) pathway is proposed for this hydroxylation reaction.


Subject(s)
Palladium/chemistry , Catalysis , Hydroxylation , Oxygen/chemistry , Water/chemistry
16.
Chemistry ; 20(14): 3932-8, 2014 Apr 01.
Article in English | MEDLINE | ID: mdl-24590598

ABSTRACT

A transition-metal-free oxidative C-N coupling method has been developed for the synthesis of 1H-azaindazoles and 1H-indazoles from easily accessible hydrazones. The procedure uses TEMPO, a basic additive, and dioxygen gas as the terminal oxidant. This reaction demonstrates better reactivity, functional group tolerance, and broader scope than comparable metal catalyzed reactions.


Subject(s)
Indazoles/chemistry , Metals/chemistry , Catalysis , Molecular Structure , Oxidative Coupling
17.
Org Lett ; 14(19): 5030-3, 2012 Oct 05.
Article in English | MEDLINE | ID: mdl-22988906

ABSTRACT

An unprecedented ruthenium(II)-catalyzed intramolecular oxidative C-N coupling method has been developed for the facile synthesis of a variety of synthetically challenging tri- and tetrasubstituted pyrazoles. Dioxygen gas is employed as the oxidant in this transformation. The reaction demonstrates excellent reactivity, functional group tolerance, and high yields.


Subject(s)
Oxidative Coupling , Pyrazoles/chemistry , Ruthenium/chemistry , Catalysis , Kinetics , Molecular Structure
18.
Chem Commun (Camb) ; 47(36): 10133-5, 2011 Sep 28.
Article in English | MEDLINE | ID: mdl-21826369

ABSTRACT

A new efficient copper-catalyzed intramolecular amination reaction has been developed to readily synthesise a wide variety of multi-substituted 2H-indazole and 1H-pyrazole derivatives from easily accessible starting materials under mild conditions. A highly selective ligand for estrogen receptor ß was prepared in three steps by employing this method.


Subject(s)
Copper/chemistry , Indazoles/chemistry , Pyrazoles/chemistry , Catalysis , Cyclization
SELECTION OF CITATIONS
SEARCH DETAIL
...